The estimated Net Worth of Enrique J. Carrazana is at least $919 Tisíc dollars as of 1 December 2015. Enrique Carrazana owns over 7,218 units of Marinus Pharmaceuticals Inc stock worth over $44,686 and over the last 13 years he sold MRNS stock worth over $715,149. In addition, he makes $158,963 as Independent Director at Marinus Pharmaceuticals Inc.
Sign up
Enrique Carrazana MRNS stock SEC Form 4 insiders trading
Enrique has made over 8 trades of the Marinus Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 7,218 units of MRNS stock worth $274,861 on 1 December 2015.
The largest trade he's ever made was exercising 97,993 units of Marinus Pharmaceuticals Inc stock on 8 January 2015 worth over $2,406,708. On average, Enrique trades about 5,442 units every 52 days since 2012. As of 1 December 2015 he still owns at least 32,148 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Enrique Carrazana stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Enrique Carrazana biography
Dr. Enrique J. Carrazana M.D. serves as Independent Director of the Company. Dr. Carrazana has served as Chief Medical Officer of Neurelis, Inc. since April 2020. Before that, he served as a consultant to a number of life science companies starting in January 2016, including to Neurelis, Inc. from December 2016 to April 2020, and served as a consultant for a number of other life science companies from January 2016 to December 2016. Dr. Carrazana is the former Chief Medical Officer of Acorda Therapeutics, Inc. (Nasdaq: ACOR), where he served from October 2011 to January 2016, and was responsible for the management of drug development programs and regulatory filings, as well as the company’s medical affairs and drug safety departments. Previously, Dr. Carrazana held various medical leadership roles at Novartis International AG (NYSE: NVS), where his last role was Vice President, Global Head Development Established Medicines Franchise based in Basel, Switzerland. He was also Director of the Epilepsy Center of Excellence at the Miami Veterans’ Administration (VA) Hospital and Associate Professor of Neurology at the University of Miami Miller School of Medicine. Dr. Carrazana currently serves on the board of directors of Hawaii Biotech, Inc. Dr. Carrazana is a board-certified neurologist with more than 20 years of experience in the pharmaceutical industry and clinical practice. He has presented and published a wide range of research on various neurology topics, with an emphasis on epilepsy. Dr. Carrazana received an M.D. from the Harvard Medical School and completed his residency in neurology and fellowship in neurophysiology at the Harvard Longwood Neurology Program. Carrazana's medical background and experience in pharmaceutical development qualify him to serve on our Board.
What is the salary of Enrique Carrazana?
As the Independent Director of Marinus Pharmaceuticals Inc, the total compensation of Enrique Carrazana at Marinus Pharmaceuticals Inc is $158,963. There are 11 executives at Marinus Pharmaceuticals Inc getting paid more, with Scott Braunstein having the highest compensation of $2,245,680.
How old is Enrique Carrazana?
Enrique Carrazana is 58, he's been the Independent Director of Marinus Pharmaceuticals Inc since 2013. There are 7 older and 6 younger executives at Marinus Pharmaceuticals Inc. The oldest executive at Marinus Pharmaceuticals Inc is Martha E. Manning, 66, who is the VP, Gen. Counsel & Sec..
What's Enrique Carrazana's mailing address?
Enrique's mailing address filed with the SEC is C/O MARINUS PHARMA, 5 RADNOR CORP CENT,, SUITE 500 100 MATSONFORD RD, RADNOR, PA, 19087.
Insiders trading at Marinus Pharmaceuticals Inc
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... a Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.
What does Marinus Pharmaceuticals Inc do?
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
What does Marinus Pharmaceuticals Inc's logo look like?
Complete history of Enrique Carrazana stock trades at Acorda Therapeutics Inc a Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc executives and stock owners
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Scott Braunstein,
President, Chief Executive Officer, Director -
Edward Smith,
Chief Financial Officer -
Dr. Scott N. Braunstein M.D.,
CEO, Pres & Director -
Dr. Scott Braunstein,
CEO, Pres & Director -
Edward F. Smith CPA,
Consultant -
Dr. Joseph Hulihan M.D.,
Chief Medical Officer -
Joseph Hulihan,
Chief Medical Officer -
Timothy Mayleben,
Independent Director -
Nicole Vitullo,
Chairman of the Board -
Michael Dougherty,
Independent Director -
Seth Fischer,
Independent Director -
Enrique Carrazana,
Independent Director -
Elan Ezickson,
Independent Director -
Charles Austin,
Director -
Sasha Damouni Ellis,
Vice President of Investor Relations -
Martha Manning,
Vice President, General Counsel, Secretary -
Dr. Kimberly A. McCormick Pharm.D., PharmD,
Sr. VP of Regulatory Affairs -
Sonya Weigle,
VP of HR -
Lisa Lejuwaan,
VP of Sales -
Steven E. Pfanstiel C.M.A., M.B.A.,
CFO & Treasurer -
Dr. Kimberly A. McCormick,
VP of Regulatory Affairs -
Christy Shafer,
Chief Commercial Officer -
Dr. Alex Aimetti,
Head of Scientific Affairs -
Rose McKinley,
VP of HR & Organizational Devel. -
Thomas J. Lyons,
VP of Corp., Bus. Devel. & Commercial Planning -
Martha E. Manning,
VP, Gen. Counsel & Sec. -
Stephen M Bloch,
Director -
Christopher Michael Cashman,
PRESIDENT AND CEO -
Jay Shepard,
Director -
Anand Sofinnova Venture Par...,
-
Anand Mehra,
Director -
Gail M Farfel,
Chief Clinical Dev & Reg -
Vii L P Canaan Partners Vii...,
-
Albena Patroneva,
Chief Medical Officer -
Masuoka K. Lorianne,
Chief Medical Officer -
Capital Life Sciences Inves...,
-
Christine Berni Silverstein,
-
Sara Nochur,
-
Anton Gopka,
Director -
Partners Vi, L.P.Blair Jame...,
-
Vi Associates, L.P.Blair Ja...,
-
Marvin Johnson,
-
Santiago Arroyo,
Director -
Sarah B. Noonberg,
-
Christina Shafer,
CHIEF COMMERCIAL OFFICER -
Steven Pfanstiel,
CFO AND COO